Developing a Patient Specific Dendritic Cell Immunotherapy that Shows Effective Patient Response
Time: 8:30 am
day: Conference Day One
Details:
- Developing a personal, precision medicine that minimizes adverse events and maximizes efficacy
- Employing a pan-antigenic approach to protect against mutation-associated loss of function for more powerful therapeutics vaccines
- Diving into promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival of patients
